Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis

Hiroyuki Ariyasu; Hiroshi Iwakura; Naoichiro Yukawa; Toshinori Murayama; Masayuki Yokode; Harue Tada; Kenichi Yoshimura; Satoshi Teramukai; Tatsuya Ito; Akira Shimizu; Atsushi Yonezawa; Kenji Kangawa; Tsuneyo Mimori; Takashi Akamizu

doi:10.1507/endocrj.EJ14-0088

Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis

Hiroyuki Ariyasu, Hiroshi Iwakura, Naoichiro Yukawa, Toshinori Murayama, Masayuki Yokode, Harue Tada, Kenichi Yoshimura, Satoshi Teramukai, Tatsuya Ito, Akira Shimizu, Atsushi Yonezawa, Kenji Kangawa, Tsuneyo Mimori, Takashi Akamizu

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The majority of patients with systemic sclerosis (SSc) have gastrointestinal (GI) tract involvement, but therapies using prokinetic agents are usually unsatisfactory. Ghrelin stimulates gastric motility in healthy human volunteers. In this study, we investigated whether ghrelin could improve gastric emptying in patients with gastrointestinal symptoms due to SSc. The study was performed in a randomized, double-blind, placebo-controlled crossover fashion on two occasions. Ten SSc patients with GI tract involvement received an infusion of either ghrelin (5.0 μg/kg) or saline, and gastric emptying rate was evaluated by ¹³C-acetic acid breath test. Gastric emptying was significantly accelerated by ghrelin infusion in patients with SSc (ghrelin vs. saline: 43.3 ± 11.4 min vs. 53.4 ± 5.4 min, P=0.03). No serious adverse effects were observed. Our results suggest that ghrelin might represent a new therapeutic approach for GI tract involvement in patients with SSc.

Original language	English
Pages (from-to)	735-742
Number of pages	8
Journal	Endocrine journal
Volume	61
Issue number	7
DOIs	https://doi.org/10.1507/endocrj.EJ14-0088
Publication status	Published - 2014
Externally published	Yes

Keywords

Gastric motility
Ghrelin
Systemic sclerosis

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1507/endocrj.EJ14-0088

Cite this

@article{e7313ba30f9c4d4abf677472d079d5c7,

title = "Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis",

abstract = "The majority of patients with systemic sclerosis (SSc) have gastrointestinal (GI) tract involvement, but therapies using prokinetic agents are usually unsatisfactory. Ghrelin stimulates gastric motility in healthy human volunteers. In this study, we investigated whether ghrelin could improve gastric emptying in patients with gastrointestinal symptoms due to SSc. The study was performed in a randomized, double-blind, placebo-controlled crossover fashion on two occasions. Ten SSc patients with GI tract involvement received an infusion of either ghrelin (5.0 μg/kg) or saline, and gastric emptying rate was evaluated by 13C-acetic acid breath test. Gastric emptying was significantly accelerated by ghrelin infusion in patients with SSc (ghrelin vs. saline: 43.3 ± 11.4 min vs. 53.4 ± 5.4 min, P=0.03). No serious adverse effects were observed. Our results suggest that ghrelin might represent a new therapeutic approach for GI tract involvement in patients with SSc.",

keywords = "Gastric motility, Ghrelin, Systemic sclerosis",

author = "Hiroyuki Ariyasu and Hiroshi Iwakura and Naoichiro Yukawa and Toshinori Murayama and Masayuki Yokode and Harue Tada and Kenichi Yoshimura and Satoshi Teramukai and Tatsuya Ito and Akira Shimizu and Atsushi Yonezawa and Kenji Kangawa and Tsuneyo Mimori and Takashi Akamizu",

year = "2014",

doi = "10.1507/endocrj.EJ14-0088",

language = "English",

volume = "61",

pages = "735--742",

journal = "Endocrine Journal",

issn = "0918-8959",

publisher = "Japan Endocrine Society",

number = "7",

}

TY - JOUR

T1 - Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis

AU - Ariyasu, Hiroyuki

AU - Iwakura, Hiroshi

AU - Yukawa, Naoichiro

AU - Murayama, Toshinori

AU - Yokode, Masayuki

AU - Tada, Harue

AU - Yoshimura, Kenichi

AU - Teramukai, Satoshi

AU - Ito, Tatsuya

AU - Shimizu, Akira

AU - Yonezawa, Atsushi

AU - Kangawa, Kenji

AU - Mimori, Tsuneyo

AU - Akamizu, Takashi

PY - 2014

Y1 - 2014

N2 - The majority of patients with systemic sclerosis (SSc) have gastrointestinal (GI) tract involvement, but therapies using prokinetic agents are usually unsatisfactory. Ghrelin stimulates gastric motility in healthy human volunteers. In this study, we investigated whether ghrelin could improve gastric emptying in patients with gastrointestinal symptoms due to SSc. The study was performed in a randomized, double-blind, placebo-controlled crossover fashion on two occasions. Ten SSc patients with GI tract involvement received an infusion of either ghrelin (5.0 μg/kg) or saline, and gastric emptying rate was evaluated by 13C-acetic acid breath test. Gastric emptying was significantly accelerated by ghrelin infusion in patients with SSc (ghrelin vs. saline: 43.3 ± 11.4 min vs. 53.4 ± 5.4 min, P=0.03). No serious adverse effects were observed. Our results suggest that ghrelin might represent a new therapeutic approach for GI tract involvement in patients with SSc.

AB - The majority of patients with systemic sclerosis (SSc) have gastrointestinal (GI) tract involvement, but therapies using prokinetic agents are usually unsatisfactory. Ghrelin stimulates gastric motility in healthy human volunteers. In this study, we investigated whether ghrelin could improve gastric emptying in patients with gastrointestinal symptoms due to SSc. The study was performed in a randomized, double-blind, placebo-controlled crossover fashion on two occasions. Ten SSc patients with GI tract involvement received an infusion of either ghrelin (5.0 μg/kg) or saline, and gastric emptying rate was evaluated by 13C-acetic acid breath test. Gastric emptying was significantly accelerated by ghrelin infusion in patients with SSc (ghrelin vs. saline: 43.3 ± 11.4 min vs. 53.4 ± 5.4 min, P=0.03). No serious adverse effects were observed. Our results suggest that ghrelin might represent a new therapeutic approach for GI tract involvement in patients with SSc.

KW - Gastric motility

KW - Ghrelin

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84905171656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905171656&partnerID=8YFLogxK

U2 - 10.1507/endocrj.EJ14-0088

DO - 10.1507/endocrj.EJ14-0088

M3 - Comment/debate

C2 - 24739333

AN - SCOPUS:84905171656

SN - 0918-8959

VL - 61

SP - 735

EP - 742

JO - Endocrine Journal

JF - Endocrine Journal

IS - 7

ER -

Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this